|
Market Cap (5-Jul) $86,511,600 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (19-Jun) 190,561 (0.07%) (455th) |
|
52w High $0.57 |
52w Low $0.275 |
P/E - |
EPS -0.09 |
RCE released this announcement to the ASX on 22 November 2021, 9:57. The announcement is not marked as price sensitive, and is 11 page(s) in length and 2.06MB in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.330% short sold according to ASIC data. It was ranked the 337th most shorted stock on the ASX. It remains ranked 455th as of the latest reported data (19 June 2025).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| AGM Presentation | 22 November 2021, 9:57 |
| Opening R&D Address at World AMR Congress | 8 November 2021, 10:30 |
| Appendix 4C and Activity Report | 29 October 2021, 11:48 |
| Ethics Approval to Start Phase 1 Intravenous Clinical Trial | 25 October 2021, 10:17 |
You must be logged in to post a reply.
Recce Pharmaceuticals Ltd 